Lactylation in pancreatic cancer: From molecular mechanisms to therapeutic perspectives

Read full text Summarise with VIRAT
Authors: Gabriel Dickson Hawanga, Zhaoxing Li, Mao-Xin Li, Xiulei Zhang, Daohai Qian
Cited by: 0
References: 12

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy characterized by intense metabolic reprogramming and an immunosuppressive tumor microenvironment. The recent discovery of lactylation, a novel post-translational modification derived from lactate, provides a direct molecular link between glycolysis and the regulation of gene expression. This review synthesizes the emerging role of lactylation in PDAC pathogenesis. We detail how a lactate-rich microenvironment fuels the lactylation of histones and non-histone proteins, driving oncogenic processes such as transcriptional reprogramming, maintenance of lineage plasticity, and therapeutic resistance. Furthermore, lactylation in stromal and immune cells reinforces immunosuppression, facilitating tumor progression. We critically evaluate the translational potential of targeting this axis through inhibitors of lactate production, transport, or the epigenetic writers themselves. While promising, these strategies face significant challenges, including achieving molecular specificity and overcoming drug delivery barriers in PDAC. We conclude that lactylation represents a critical metabolic-epigenetic link in PDAC and a compelling therapeutic target worthy of further investigation.

Fields of Study & Subjects

Cancer Hypoxia and Metabolism Pancreatic and Hepatic Oncology Research Epigenetics and DNA Methylation

Publication details

Journal / source
World Journal of Clinical Oncology
Volume
17
Issue
3
Publication date
23 March 2026
Language
EN